121 results about "Breast carcinoma" patented technology

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as breast carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against breast or cancer.

The invention relates to a sticking plaster used for treating lumps in breast, and is prepared by the following raw materials: radix bupleuri, nutgra galingale rhizome, bitter orange, szechwan chinaberry fruit, cistanche salsa, barrenwort, common burreed rhizome, rhizoma zedoariae, pangolin, szechuan lovage rhizome, radix curcumae, frankincense, myrrh, rhizoma corydalis, nux vomica, dragon's blood, cowherb seed, safflower, peach seed, euphorbia kansui, snakegourd fruit, gleditsia sinensis sting, airpotato yam, seaweed, raw rhizoma arisaematis, raw tuber pinellia, white mustard seed, oyster, portulaca grandiflora hook, iphigenia indica, paridin, oldenlandia diffusa, dandelion, red paeonia, Chinese goldthread, yellowcypress, rhubarb, raw szechuan aconite, raw wild aconite, datura flower, cinnamon, white pepper, asarum, angelica dahurica, scorpion and centipede. With reasonable compatibility, the invention has the functions of soothing liver, regulating qi, activating blood circulation, removing stasis, softening hard lumps, dispelling nodes, clearing away heat and toxic material, releasing swelling and stopping pain. The invention has wide medicinal odour, large dosage, strong efficacy and definite curative effect. Patients have no pain for application, and the cost is low; the effective rate of treatment is 98.62 percent, and the cure rate can reach 96.77 percent; the application of the sticking plaster can effectively prevent the occurrence of breast carcinoma.

The invention disclose a pulchritude of neoplasm sera, which made up of peptide metarginase; among of which tumor is that one of breast carcinoma, liver cancer, renal carcinoma, oophoroma, carcinoma of prostate and bladder carcinoma. The invention also disclose the application of pulchritude of neoplasm sera in the clinical diagnosis reagent of preparing detect tumor. Using the tumor clinical diagnosis reagent or kit which is provided by this invention and prepared pulchritude of neoplasm sera, it can detect a guideline and realize preparatory ensure if the tester suffer from malignancy, accomplish the work of health screening with low cost in the short detect time, and provide the reliable basis for the clinical diagnosis.

A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of encapsulated the plasmids, oligonucleotides or negatively-charged drugs with HSV-tk plus encapsulated ganciclovir.

A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir.

The invention discloses a detection primer combination and a kit for HER2 (human epidermal growth factor receptor 2) gene amplification. The detection primer combination comprises an HER2 primer combination and a GAPDH reference primer combination; each combination comprises upstream and downstream amplification primers of a target gene of the combination and a Taqman fluorescent probe. The kit comprises the detection primer combination, a positive quality control and a negative quality control. By using the detection primer combination and the kit, whether the HER2 gene in patients with breast carcinoma is amplified or not can be detected quickly and simply; compared with the FISH (fluorescent in situ hybridization) method, a method using the detection primer combination and the kit is high in detection sensitivity, low time consumption, generally 1.5 to 2 hours for acquiring reaction results, low in cost, low in false positive ratio, and suitable for large-scale clinical development; thus, quick, effective and accurate detection is achieved for HER2 gene amplification, and timely disease treatment and treatment effect monitoring are guaranteed.

The invention discloses a molecular marker for diagnosing breast cancer, which is used for detecting expression of the thioredoxin (TRX) and the thioredoxin binding protein 2 (TRX-binding protein-2, TBP-2) in surrounding normal breast tissue and mass tissue. A protein immunoblot experiment is used for detecting the expression amount of the thioredoxin and the thioredoxin binding protein 2; in breast mass tissue, the expression of the thioredoxin is increased and the expression of the thioredoxin binding protein 2 is decreased; as significant difference exists between the breast mass tissue and the normal breast tissue, the thioredoxin and the thioredoxin binding protein 2 can be used as a new molecular marker of breast cancer and used for the clinical diagnosis of breast cancer.

The invention relates to Chinese medicine preparation for curing cancer and a method for preparing the same, which belong to the medicine technical field and are used for solving the problem of curing a plurality of cancers and particularly curing intermediate and advanced patients. The medicine preparation takes blue vitriol, realgar, centipede, cabardine, bornyl alcohol, secretio bufonis, scorpion, zaocys, woodlouse, raw oysters, honeycombs and herba salviae chinensis as raw materials which are prepared into pills through mixture and crushing. The medicine preparation is formed by excavation, sorting, research and development of a hereditary secret formula which is handed down for hundreds of years. The medicine preparation has strong medicine potency and obvious effect and has the function of curing and saving intermediate and advanced patients of a plurality of cancers. The functions of the medicine preparation are as follows: reducing edema and reducing phlegm, astringing and softening hard mass, resolving stasis and promoting menstruation, inducing vomiting and expelling toxin, detoxicating and alleviating pain, and anti-cancer and inducing resuscitation. The medicine preparation can be used for curing gastric cancer, lung cancer, liver cancer, skin carcinoma, breast carcinoma, intracranial tumour and other nameless malignant pyogenic infections. The medicine preparation is characterized by short taking time, quickness in taking effect and so on; the patients are required to take the medicine as directed by a physician severely; and the medicine plays a part in bringing the dying back to life on partial cancer patients as shown by clinical observation.

The invention provides a new molecular marker hsa-miR-374a of breast carcinoma, that is, non-coding RNA gene hsa-miR-374a of micromolecule as a molecular marker of breast carcinoma. Expression of the molecular marker in tissues suffering from breast carcinoma is obviously higher than that of normal mammary tissues, and is associated with clinical classification of breast carcinoma, and expression of hsa-miR-374a in breast carcinoma cell line cultured in vitro is higher than that of normal mammary epithelial cells and immortalized normal mammary epithelial cells. The invention further provides application of the molecular marker of breast carcinoma to preparing an anti-breast cancer drug. The drug comprises effective amount of blocker capable of blocking expression of non-coding RNA gene hsa-miR-374a of micromolecule. The molecular marker provides new effective way for diagnosing and treating breast carcinoma. The invention also provides certain experience and foundation for further research of function of hsa-miR-374a and relation with other tumors.

A dual-waveband infrared instrument for diagnosing mastopathy is composed of a hand-held laser source consisting of single-source laser probe and multi-source laser probe with multiple laser heads and their positions regulator, an infrared detecting system consisting of optical splitting system, near infrared camera head and far infrared camera head, and a data processing and computer control system.

The invention discloses a Chinese medicinal composition for treating diminished ovarian reserve and application thereof. The composition comprises postmenstrual Chinese medicinal composition, intermenstrual Chinese medicinal composition, premenstrual Chinese medicinal composition and menstrual Chinese medicinal composition, has the functions of replenishing essence, tonifying kidney, nourishing blood and regulating menstruation and has unique advantages for treating the diminished ovarian reserve; the ovarian reserve function can be obviously improved and normal menstruation can be recovered;the short-term effect of the composition is equivalent to that of hormone replacement therapy, and the long-term effect of the composition is superior to that of the hormone replacement therapy; and the composition does not have the side effect of inducing diseases such as breast carcinoma and the like of the hormone replacement therapy, is a clinically safe and effective pure Chinese medicinal preparation and can be used for preparing a medicament for treating the diminished ovarian reserve.

The invention discloses a traditional Chinese medicine for treating breast carcinoma, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine consists of the following raw materials by weight: 10 g of astragalus root, 10 g of codonopsis pilosula, 10 g of fruit of fiverleaf akebia, 10 g of red peony root, 10 g of green tangerine peel, 10 g of curcuma zedoary, 9 g of frankincense, 9 g of myrrh, 9 g of tree-cultivated ganoderma lucidum, 9 g of cyperus rotundus, 6 g of turmeric root-tuber, 6 g of Indian iphigenia bulb, 6 g of rhizoma curculiginis and 6 g of liquoric root. The medicaments in the formula act cooperatively; and the traditional Chinese medicine has the advantages of extremely strong effects of invigorating vital energy and solidifying superficies, relieving liver for smoothing qi, activating blood and dispersing accumulation, diminishing inflammation and stopping pain, convenience for use, low cost and obvious curative effect on the breast carcinoma.

The invention discloses applications of CIZI gene and relevant medicines, discloses applications of CIZI gene in preparation or screening of oncological therapeutic medicines of liver cancer, lung cancer, breast carcinoma or glioma, further constructs separated nucleic acid molecules, CIZI gene interference nucleic acid construction bodies and CIZI gene interference lentivirus which can decrease expression of CIZI gene in tumor cells and discloses applications thereof. The nucleic acid molecules, nucleic acid construction bodies or CIZI gene interference lentivirus can inhibit the expression of the CIZI gene specifically. Especially, lentivirus can infect target cells efficiently, the expression of the CIZI gene in the target cells is inhibited efficiently, furthermore the growth of the tumor cells is inhibited, the apoptosis of the tumor cells is promoted, and the applications of CIZI gene and the relevant medicines are significant in oncotherapy.

The present invention relates generally to the use and application of compounds or agents, including somatostatin analogs, with effect on, affinity for, or specificity to SSTR3 and/or SSTR5 somatostatin receptors, particularly in the breast, for the treatment of breast hyperplasia, pre-neoplastic lesions and breast carcinoma and/or prevention or reduction of risk for breast cancer or treatment of breast cancer, including DCIS. The invention also relates to use of somatostatin analog SOM230 in treatment of breast hyperplasia and/or prevention or treatment of breast cancer. The invention includes assays and methods for screening and identifying breast hyperplasia with elevated SSTR3 and/or SSTR5 receptors and for chemotherapy and identifying compounds of use in the invention which are specific for, modulate via, or bind to SSTR3 and/or SSTR5 receptors.

The invention provides a breast carcinoma early-stage detecting instrument based on annular array opto-acoustic sensing technology. The breast carcinoma early-stage detecting instrument based on the annular array opto-acoustic sensing technology comprises a detecting bed, an optical excitation unit, a signal collecting unit, a signal processing unit, a sensing unit, an outer controlling unit and an image displaying unit. A detecting window is formed in the detecting bed. A light permeating glass outer shell is arranged below the detecting window. The optical excitation unit comprises an annular array impulse laser tube, a lens system and a drive circuit. The signal collecting unit is a multiple-channel parallel collecting system. The sensing unit comprises an annular array supersonic sounding device, a supersonic coupling agent and a sealed container. The breast carcinoma early-stage detecting instrument based on the annular array opto-acoustic sensing technology is simple in structure, convenient to operate, low in cost, high in integration degree, easy to apply and popularize, capable of integrating opto-acoustic excitation, coupling and sensing and capable of achieving a small and practical system structure and meets the requirement of breast carcinoma clinical detection, obtains opto-acoustic cross-sectional images in the depth direction of a breast in real time and achieves breast carcinoma early-stage detection by carrying out CT scanning on the breast tissue.

The invention relates to a method for preparing Lonicera macranthoides saponin and its application in treating liver cancer, breast cancer and carvical carcinoma. Said method comprises following steps: extracting Lonicera macranthoides and bud with ethanol, decoloring with active carbon, grading in macroreticular resinous column or polyamide column, washing with ethanol, basic hydrolyzing, decoloring with active carbon for the second time, crystallizing and getting said product. The invention is characterized by high productivity and purity of effective component, which is about 98%, and is especially for large- scale production. The effective dosage of Lonicera macranthoides saponin is toxic to external cancer cell, and inhibitive to mouse liver cancer H22, mouse S180 cancer and Lewis lung cancer.

The invention provides a general formula I compound, namely, an application of N-(4-(3- chlorine-4-(3-fluorine-benzyloxy) phenyl amidocyanogen]-quinazoline-6-radical-}-acrylamide or N-(4-(3-chlorine-4-(3-fluorine-benzyloxy) phenyl amidocyanogen)-7-methoxy-quinazoline-6- radical-)-acrylamide in preparing an antineoplastic, in particular to the application in preparing the antineoplastic for treating highly expressed epidermal growth factor receptor. The compound general formula I particularly provides an application of the general formula I compound in preparing drugs for treating erb-B2 highly expressed tumors, such as erb-B2 highly expressed lung cancer, ovarian cancers and breast carcinoma, etc.

A hybrid system is developed using thermal and electrical impedance imaging methods together. The innovation of the approach relies on the frequency dependence of the tissue's electrical impedance which facilitates the acquisition of multiple thermal images with currents at different frequencies injected to the region of the body under inspection. Proposed method without current application (in passive mode of operation) provides images which are obtained by standard thermal imagers. On the other hand, the application of the electrical current (in active mode of operation) increases the temperature contrast on the body surface depending on the electrical property of tissue. Therefore, the technique while increasing the thermal contrast provides frequency dependent conductivity distribution data which can be used as a basis for the detection of the breast carcinoma. The sensitivity of the technique is increased by an infrared camera with dual band (MWIR/LWIR) imaging capability.

The invention relates to genomics, molecular biology, cell biology, gene engineering and clinical medicine, in particular to application of a human ING4 and IL-24 double-gene coexpression vector as a radiotherapy sensitizing agent. Before the radiotherapy, the human ING4 and IL-24 double-gene coexpression vector is led in tumor cells so that the human ING4 and IL-24 genes are expressed in the tumor cells, and then the radiotherapy is carried out. The Ad-ING4-polyA<delta 296-298>+CMV-IL-24 can retard lots of tumor cells in the proliferative stage in the G2/M stage and is beneficial to enhancing the irradiation sensitivity. The MTT and the FCM detection results further show that the Ad-ING4-IL-24 combined radiotherapy has the effect of obviously inhibiting the growth of the SPC-A1 lung adenocarcinoma cells, MDA-MB-231 breast carcinoma cells and the transplanted tumor thereof and inducing the cell apoptosis, exceeds the Ad-ING4-IL-24 single genome and the radiotherapy single genome, and presents obvious radiotherapy sensitization synergistic effect. Therefore, the human ING4 and IL-24 double-gene coexpression vector can be used for enhancing the sensitivity of the tumor cells to the radiotherapy.